



**SERES**  
THERAPEUTICS

Seres Therapeutics Investor Presentation  
November 13, 2024



# Disclaimers

## Forward Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including statements about the financial terms and future payments related to the VOWST sale; the timing and results of our clinical studies and data readouts; future product candidates, development plans and commercial opportunities; interactions with regulatory agencies; operating plans and our future cash runway; our ability to generate additional capital; our planned strategic focus; anticipated timing of any of the foregoing and other statements which are not historical fact.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: (1) we have incurred significant losses, are not currently profitable and may never become profitable; (2) our need for additional funding; (3) our history of operating losses; (4) our novel approach to therapeutic intervention; (5) our reliance on third parties to conduct our clinical trials and manufacture our product candidates; (6) the competition we will face; (7) our ability to protect our intellectual property; (8) our ability to retain key personnel and to manage our growth; (9) the effect of the VOWST sale on our ability to retain and hire key personnel and maintain relationships with our customers, suppliers, advertisers, partners and others with whom we do business, or on our operating results and businesses generally; (10) the risks associated with the disruption of management's attention from ongoing business operations due to the obligation to provide transition services; (11) our failure to receive the installment payments or the milestone payments in the future; (12) the uncertainty of impact of the 50/50 profit and loss sharing arrangement on our reported results and liquidity; and (13) we may not be able to realize the anticipated benefits of the VOWST sale. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), on August 13, 2024, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this communication. Any such forward-looking statements represent management's estimates as of the date of this communication. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this communication.

# Transforming patient outcomes using proprietary consortia of live biotherapeutics

## Strong foundation

- Validated platform with VOWST® clinical and regulatory success
- Asset sale strengthens balance sheet, expected to extend runway into Q4 '25
- Wholly-owned cultivated pipeline: SER-155, SER-147, beyond

## Favorable Phase 1b clinical data in SER-155 allo-HSCT

- 77% relative risk reduction for bloodstream infections
- Significant reduction in systemic antibacterial exposure
- Lower incidence of febrile neutropenia
- Well tolerated safety profile; no treatment-related SAEs

## Blockbuster opportunity

- Accelerate SER-155 development in allo-HSCT
- Potential to initiate multiple clinical studies in the next 12-18 months
- Potential to evaluate SER-155 in additional populations at high risk of serious bacterial infections (e.g., autologous HSCT, blood cancers, CAR-T)

## Expansive potential

- Current focus of preventing life-threatening infections
- SER-147 designed to prevent infections in chronic liver disease
- Longer-term potential to treat immune-related diseases (including IBD)

**Company is pursuing SER-155 strategic partnership to accelerate next study in allo-HSCT and expand to multiple target populations**

# Validated platform: Seres pioneered the development and FDA approval of VOWST as the first-ever oral live microbiome therapeutic



**VOWST™**  
(fecal microbiota spores, live-brpk)

FDA approved (April 2023)  
to prevent the recurrence of  
*C. difficile* infection in adults


**DRAMATIC CLINICAL BENEFIT –**  
*Preventing infection recurrence*

Approximately

**88%**

sustained clinical response rate  
(*C. diff.* recurrence, at up to 8 weeks)

# VOWST asset sale completed September 30, 2024: transformational for Seres – provides resources to support SER-155 advancement



- **VOWST asset purchase agreement provided infusion of capital and supports SER-155 development**
- **Asset sale extends operational runway into Q4 2025**
- **Retires debt and other obligations**

## KEY FINANCIAL TERMS

**\$100M** upfront payment to Seres, less ~\$20M in net obligations due to an affiliate of SPN\*

**\$15M** equity investment by SPN at closing

**\$60M** prepaid sales-based milestone at closing

**\$75M** in deferred payments due in 2025 (less ~\$1.5M in employment-related payments)

**\$275M** in potential future sales-based milestone payments (subject to reductions for interest on prepaid milestone payment)

**Transaction results in a more streamlined, focused Seres organization and lower cash burn rate**

# Near-term focus on SER-155 as anchor biotherapeutic program



- Reduces risk of recurrent *C. diff* infections
- Well tolerated safety profile

Program	Lead Indication & Development Stage	Therapeutic Objectives	Potential Additional Indications
<b>SER-155</b>	<u>Allogeneic HSCT:</u> Phase 1b Cohort 2 (placebo controlled) data announced Sept. '24	Reduce incidence of serious bacterial infections (e.g., BSIs), febrile neutropenia, and GvHD	<ul style="list-style-type: none"> <li>• Autologous HSCT</li> <li>• Blood cancers</li> <li>• CAR-T</li> </ul>
<b>SER-147</b>	<u>Chronic liver disease:</u> IND-enabling activities	Reduce incidence of serious bacterial infections (e.g., SBP, BSIs) and related complications	<ul style="list-style-type: none"> <li>• Solid organ transplant</li> <li>• ICU patients</li> <li>• Long-term care patients</li> </ul>

Engaging with FDA to explore **potential for SER-155 to have single registrational study for efficacy**, following successful precedent from VOWST

# Potential to treat a range of vulnerable patient populations

## Target population characteristics



GI microbiome functional disruption



Immune suppression




Antibiotic use



Neutropenia



Time in hospital/care settings



Lost epithelial or mucosal barrier integrity

## Potential to prevent bacterial infections and immune-related disease


### Prevent life-threatening infections (current focus)

- Blood cancers (including HSCT, CAR-T)
- Solid organ transplant
- ICU & long-term care patients
- Chronic liver disease

### Treat immune-related diseases

- Inflammatory bowel disease
- Graft vs. host disease (GvHD)
- Checkpoint colitis
- Radiation enteritis

# GI microbiome functional disruption leads to disease susceptibility




## IMPACTED BIOLOGY

- Pathogen domination
- Lost barrier & mucosal integrity
- Unfavorable immune responses



# Seres' biotherapeutics designed to restore functionality and health



# Seres' biotherapeutics and pipeline candidates are expected to have well tolerated safety profile, reducing development risk

- ✓ Based on GI bacteria naturally **found in healthy humans**, and not associated with disease
- ✓ VOWST product profile includes **well tolerated safety** without drug-related serious adverse events
- ✓ **Well tolerated safety profile in multiple clinical trials** and patient populations, including medically vulnerable allo-HSCT recipients


**Safety profile has potential to mitigate a primary cause of drug development failure**

# Allo-HSCT regimen can result in potentially life-threatening complications

SER-155

- Investigational live oral biotherapeutic cultivated from clonal master cell banks
- Designed to prevent GI-derived bacterial bloodstream infections (BSIs) and other pathogen-associated complications

## Allo-HSCT treatment regimen




- **Only ~60% survival** 3 years post-transplant
- Significant **immune compromise**
- **~10% transplant mortality for adults** in first 100 days post-transplant
- **Infections are leading cause of death** in first 100 days post-transplant for adults
- Other leading causes of death are disease relapse and organ failure

# Bloodstream infections (BSI) are a leading cause of death and an escalating problem post-transplant

## Incidence


- **32-55% BSI incidence** reported in the literature
- **BSI risk escalating** due to recent adoption of post-transplant cyclophosphamide (PTCy) for GvHD prophylaxis
- ~50% of infections believed to be gut-seeded
- 50-80% febrile neutropenia incidence



## Impact

- Infection is **leading cause of death** in first 100 days post-HSCT for adults
- **~7.5% mortality rate** from bloodstream infections
- Complications including infection associated with longer hospital stay and ICU utilization, driving **substantial cost increase**

# SER-155 Phase 1b study evaluated safety, pharmacology, and efficacy in adult allo-HSCT recipients



### Primary Endpoints:

- Safety and tolerability
- SER-155 bacterial strain engraftment

### Key Secondary Endpoints through HSCT Day 100:

- Incidence of bloodstream infections (BSI), GI infections, and acute GvHD  $\geq$  Grade 2
- Incidence and duration of febrile neutropenia
- Bacterial pathogen abundance

**Received US FDA Fast Track Designation in December 2023;  
Filed for Breakthrough Therapy and Qualified Infectious Disease Product (QIDP) designations**

# Patient Safety: Cohort 2

## SER-155 was generally well tolerated with no treatment-related SAEs

### Treatment-emergent adverse events (TEAEs)

- All but one subject in the placebo arm experienced at least 1 TEAE
- Most common for SER-155 treated subjects ( $\geq 50\%$  and with  $\Delta \geq 5\%$  greater than placebo): diarrhea (86% vs. 74% placebo), nausea (62% vs. 53% placebo)
- 1/40 (3%) subject experienced a TEAE leading to treatment discontinuation (active = 0; placebo = 1)
- 3/40 (8%) subjects experienced a TEAE leading to study discontinuation (active = 1; placebo = 2)

### Serious adverse events (SAEs)

- 19/40 (48%) subjects experienced an SAE: 11/21 (52%) SER-155-treated subjects vs. 8/19 (42%) placebo-treated subjects; none considered related to SER-155 (no SUSARs)
  - Most common SAE SOC: infections & infestations (24% active vs. 37% placebo)
  - 3 deaths prior to Day 100 (active = 1; placebo = 2), 1 death after Day 100 (active), none considered related to SER-155

### Adverse events of special interest (AESIs)

- AESIs (bloodstream infections, GI infection, invasive infection): 14/40 (35%) subjects
- Rates of AESIs were lower in SER-155 arm vs placebo arm (29% vs 42% respectively)
- No SER-155 species were identified in culture from any subject

# Efficacy: SER-155 administration favorable with significant\* reduction in both bacterial BSIs and systemic antibiotic exposure; lower febrile neutropenia

Secondary Efficacy	Bloodstream infections	<b>Significant decrease</b> in bacterial bloodstream infections in SER-155-treated subjects vs. placebo
	Febrile neutropenia	<b>Numerically lower incidence rate</b> of febrile neutropenia in SER-155-treated subjects vs. placebo
	GI infections	<b>All GI infections were CDI**</b> ; 4 subjects in SER-155-treated (20%) and 2 subjects in placebo (14.3%) developed GI infections from HSCT Day 0-100
	Acute GvHD	<b>No subjects in either arm</b> developed $\geq$ Grade 3 acute GvHD; 2 subjects in each arm developed Grade 2 acute GvHD
Exploratory Efficacy	Antibacterial / antimycotic exposure	<b>Significantly lower</b> mean cumulative exposure (days) to systemic antibacterials / antimycotics for SER-155-treated subjects vs. placebo <b>Significantly lower</b> cumulative exposure rate to systemic antibacterials / antimycotics for SER-155-treated subjects vs. placebo

# Bloodstream infections from HSCT Day 0 to Day 100: Lower incidence in SER-155 treated subjects vs. placebo

Bloodstream infections from Day 0 to Day 100 (# patients)	SER-155 n=20 n (%)	Placebo n=14 n (%)
Subjects with confirmed BSI	2 (10.0%)	6 (42.9%)
95% confidence interval	(1.2, 31.7)	(17.7, 71.1)

mITT-1 population

<b>Odds ratio</b>	<b>0.15</b>
95% confidence interval	<b>(0.01, 1.13)</b>
p-value	<b>0.0423</b>

Organisms in SER-155 patients: *Finnegoldia magna*; *E. coli*/Strep mitis

Organisms in placebo patients: *E.coli*; *Enterococcus faecium*/staph haemolyticus/*Candida krusei*; *Staph aureus*; *Staph haemolyticus*; *Pseudomonas aeruginosa*; *E coli*



# Cumulative exposure to systemic antibacterials / antimycotics through HSCT Day 100: Lower incidence in SER-155 treated subjects vs. placebo

Cumulative Antibacterial or Antimycotic Exposure (HSCT Days)	SER-155 n=20 n (SD)	Placebo n=14 n (SD)
Mean (SD)	9.2 (5.44)	21.1 (20.31)
Median	9.0	14.0
Min, Max	0, 19	0, 74

Mean Difference (95% CI)

**-11.9 (-23.85, -0.04)**

mITT-1 population

p-value

**0.0494**

- Cumulative exposure is the sum of all days a subject received systemic antibacterials and/or antimycotics between HSCT Day 0 through Day 100; counting once per day regardless of number of agents taken
- 95% confidence interval and p-value based on independent samples t-test of the difference in mean days between SER-155 and placebo

# Cumulative exposure rate to systemic antibacterials / antimycotics through HSCT Day 100: Lower incidence in SER-155 treated subjects vs. placebo

Cumulative Antibacterial or Antimycotic Exposure Rate	SER-155 n=20 Rate (SD)	Placebo n=14 Rate (SD)
Mean (SD)	0.090 (0.0530)	0.305 (0.2898)
Median	0.089	0.244
Min, Max	0.00, 0.18	0.00, 0.90

Mean Difference (95% CI)

**-0.2 (-0.38, -0.05)**


mITT-1 population

p-value

**0.0163**


- Cumulative exposure rate is calculated as the sum of all days a subject received systemic antibacterials and/or antimycotics on or after HSCT Day 0 (counting once per day, regardless of number of antibacterial/antimycotic medications taken in a day) through HSCT Day 100 over the total number of days a subject was on the study from HSCT Day 0 to the earliest of EOS, or HSCT Day 100
- 95% confidence interval and p-value are based on independent samples t-test of the difference in mean days or mean rate of cumulative exposure between SER-155 and Placebo

# SER-155 Strain Engraftment: Primary objective achieved - drug bacteria strain engraftment was robust and as expected



- The majority of SER-155 strains were present at start of HSCT conditioning and durable through chemotherapy exposure
- Engraftment decreased but was detectable post-neutrophil recovery, suggesting sustained engraftment, even under unfavorable GI conditions (e.g., antibiotic exposure), and through period of greatest BSI susceptibility
- The second course of SER-155 was effective at increasing strain engraftment following transplant & neutrophil recovery, with engraftment durable out to day 100 following transplant
- Cohort 1 and Cohort 2 engraftment magnitude and kinetics had high congruence

# Pathogen Domination: Prevalence in SER-155 Cohort 2 was substantially lower relative to Historical Control Cohort



- SER-155 was designed to reduce pathogen domination that has been associated with risk of BSIs and other negative clinical outcomes<sup>1</sup>
- Observed pathogen domination events were low in the placebo and SER-155 arms with no significant differences observed
- Pathogen domination was substantially lower in SER-155 Cohort 2 compared to Historical Control Cohort<sup>2</sup>

# Hematologist-oncologist leads care team and sets protocol for treating allo-HSCT patients

Diagnosis

Pre-transplant treatment

Hematopoietic stem cell transplant (HSCT)

Key providers



**Hematologist-oncologist** (heme-onc) leads diagnosis process



**Hematologist-oncologist** makes treatment decisions and leads care team



**Pharmacist**



**Nursing**



**Pathology**



**Hematologist-oncologist** makes treatment decisions and leads expanded care team



**Infectious disease**



**Transplant support**

Key procedures

- Blood tests
- Bone marrow biopsy
- Lumbar puncture
- Chromosome and genetic analysis
- Donor matching considerations begin

- Induction chemotherapy
- Consolidation and maintenance to maintain remission

- Transplant for eligible patients
- Conditioning regimens
- Prophylactic regimens to prevent complications
- Treating complications

# Viral prophylaxis provides precedent in medically vulnerable patients

Prevymis - increasingly used for viral infection prophylaxis (e.g., allo-HSCT and solid organ transplant populations)



**\$605M '23  
WW sales**

- Reduces CMV infection in allo-HSCT recipients
- Lowers mortality rate

- Overall cost of allo-HSCT is high (~\$400K US year 1 allo-HSCT costs)
- Transplant-related complications (e.g., infections) raise cost by ~\$180K
- Infections result in longer hospital stays, readmissions, increased ICU utilization

# HCPs see SER-155 as a potentially transformative means to eliminate complications that get in the way of achieving transplant success

## Primary Value Driver for SER-155

*Reducing the risk of HSCT-related complications, thus ensuring successful engraftment and long-term health of the patient*

*A relative risk reduction of 50% in BSIs is seen as “transformative” and would support broad inclusion in standard protocols for allo-HSCT patients*



### Health Care Providers

**Streamlines the transplant process** so they can spend more time treating the patient’s underlying conditions and **less time dealing with potential morbidities**



### Patients

**One less thing to worry about** for patients already dealing with a lot; additional **financial and QoL benefits** due to shortened hospital stays



### Healthcare System

**Reduced healthcare costs** due to shorter hospital stays, fewer ICU visits, fewer antibiotic days and lower incidence of severe negative outcomes



*The benefit would be massive because people die from these infections and so preventing them, the biggest benefit is mortality. The rest of the stuff with ICU admits and sepsis protocols and all...I think some of that also gets averted. That would be huge.”*



*“This would probably be **standard of care**. It would be all eligible patients minus those who cannot tolerate it or are allergic.”*

# SER-155 has blockbuster commercial potential, driven by poor standard of care and a robust SER-155 profile

- ✓ **High unmet need** to prevent frequent and serious infections
- ✓ ~40K annual transplants worldwide; 3% annual growth from aging population and transplant success rates
- ✓ **Costly procedure** (~\$400K US year 1 allo-HSCT per patient cost) with **high incremental costs** of infections (incremental ~\$180K/patient)
- ✓ SER-155 has potentially "**transformational**" **profile** with robust efficacy and safety
- ✓ Highly concentrated universe of procedures allows **efficient commercial model** with rapid education on new standard of care



# Accelerating SER-155 clinical development with positive Ph1b outcomes

Aim to **accelerate SER-155 development** in allo-HSCT

- Potential to follow successful precedent from VOWST development with single registrational study for efficacy

**Engage with FDA on advancement of SER-155 allo-HSCT program**

- Filed for Breakthrough Therapy and Qualified Infections Disease Product designations
- Expect to receive feedback by end of 2024

Intend to evaluate SER-155 in **additional patient populations** with high risk of serious bacterial infections

**Seeking SER-155 strategic partnership to accelerate next study in allo-HSCT and expand to multiple target populations**

# Anticipated SER-155 expansion in biologically adjacent populations

<b>Population</b>	<b>Transplants / diagnoses per year (US + EU)</b>
Autologous HSCT	~30K
Blood cancers with high neutropenia rates (acute myeloid leukemia, multiple myeloma, B cell non-Hodgkin's lymphomas)	~190K

Potential to initiate multiple clinical studies within the next 12-18 months with sufficient financing

# Advancing SER-147 to prevent infections in chronic liver disease patients

## Substantial unmet need

0.5M  2.1M 

~50% experience bacterial infections in a 6 month period


~20-25% of infections are spontaneous bacterial peritonitis (SBP) and bloodstream infections likely to be gut-seeded

## Promising preclinical data


**SER-147 is an investigational live oral biotherapeutic designed to reduce pathogens causing gut-seeded SBP and BSIs in liver disease patients**

Example: 1-3 log reduction of *E. coli* in *in vitro* models, plus reduction of other pathogens


### Declining *E. coli* titers



# Manufacturing platform delivers defined consortia in oral formulation using cost-effective production



# Maximizing opportunity going forward



# Summary and path forward

## Developing a pipeline of novel live biotherapeutics in areas of high unmet need

- SER-155 Phase 1b placebo-controlled clinical efficacy data further support Seres' strategy
- Pipeline aims to bring transformative medicines to a wider set of patients, led by SER-155 while advancing SER-147
- VOWST approval validates using live biotherapeutics to prevent life-threatening infections

## SER-155 Phase 1b placebo-controlled clinical results promising

- SER-155 administration associated with 77% relative risk reduction for bloodstream infections
- SER-155 administration associated with significant reduction in systemic antibiotic exposure and lower incidence of febrile neutropenia as compared to placebo through day 100 post HSCT
- SER-155 demonstrated generally well tolerated safety profile and confirmed drug bacteria strain engraftment
- Company is pursuing SER-155 strategic partnership to accelerate next study in allo-HSCT and expand to multiple target populations

## VOWST asset sale strengthens financial position

- \$66.8M in cash at end Q3 2024; cash runway projected into Q4 2025
- Fully retired outstanding debt
- VOWST asset sale closed in September; received \$175M at closing less an ~\$20M settlement of net obligations, and \$75M (less ~\$1.5M in employment-related payments) in installment payments due in 2025 + \$275M potential future milestones